^
BIOMARKER:

HER-2 mutation

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 mutation
NSCLC
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 mutation
NSCLC
afatinib
Resistant: A2 - Guideline
HER-2 mutation
NSCLC
trastuzumab
Resistant: A2 - Guideline
HER-2 mutation
NSCLC
ado-trastuzumab emtansine
Sensitive: A2 - Guideline
HER-2 mutation
Solid Tumor
BDTX-189
Sensitive: B - Late Trials
HER-2 mutation
Breast Cancer
ribociclib
Sensitive: B - Late Trials
HER-2 mutation
Solid Tumor
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Gastric Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Urothelial Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
NSCLC
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Solid Tumor
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Cervical Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
NSCLC
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
NSCLC
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
Breast Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
HER-2 mutation
NSCLC
trastuzumab + neratinib
Sensitive: C3 – Early Trials
HER-2 mutation
NSCLC
neratinib + temsirolimus
Sensitive: C3 – Early Trials
HER-2 mutation
NSCLC
U3-1402
Sensitive: C3 – Early Trials
HER-2 mutation
Biliary Tract Cancer
neratinib
Sensitive: C3 – Early Trials
HER-2 mutation
LUAD
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 mutation
SCCHN
cetuximab + ISU104
Sensitive: C3 – Early Trials
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive: C3 – Early Trials
HER-2 mutation
Solid Tumor
KN046 + KN026
Sensitive: C3 – Early Trials
HER-2 mutation
CRC
pyrotinib
Sensitive: C3 – Early Trials
HER-2 mutation
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
HER-2 mutation
LUAD
afatinib
Sensitive: C3 – Early Trials
HER-2 mutation
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
HER-2 mutation
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 mutation
LUAD
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 mutation
HER2 Positive Breast Cancer
neratinib
Sensitive: C3 – Early Trials
HER-2 mutation
NSCLC
durvalumab
Resistant: C3 – Early Trials
HER-2 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
HER-2 mutation
Gastric Cancer
trastuzumab
Sensitive: C3 – Early Trials
HER-2 mutation
Gastric Cancer
disitamab vedotin
Sensitive: C3 – Early Trials
HER-2 mutation
Uterine Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 mutation
NSCLC
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
HER-2 mutation
Ovarian Cancer
bevacizumab
Resistant: C3 – Early Trials
HER-2 mutation
Cholangiocarcinoma
trastuzumab
Resistant: C4 – Case Studies
HER-2 mutation
Cholangiocarcinoma
lapatinib
Resistant: C4 – Case Studies
HER-2 mutation
Ovarian Cancer
dasatinib
Sensitive: D – Preclinical
HER-2 mutation
Ovarian Cancer
neratinib
Sensitive: D – Preclinical
HER-2 mutation
GastroEsophageal Cancer
dasatinib
Sensitive: D – Preclinical
HER-2 mutation
GastroEsophageal Cancer
neratinib
Sensitive: D – Preclinical
HER-2 mutation
GastroEsophageal Cancer
dasatinib + neratinib
Sensitive: D – Preclinical
HER-2 mutation
Ovarian Cancer
dasatinib + neratinib
Sensitive: D – Preclinical
HER-2 mutation
Cervical Cancer
afatinib
Sensitive: D – Preclinical